Editas Medicine, Inc.
EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.74
Price+0.87%
$0.02
1Y
Price
Market Cap
$169.368m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-291.6%
EBITDA Margin-333.0%
Net Profit Margin-414.6%
Free Cash Flow Margin-291.6%
EBITDA Margin-333.0%
Net Profit Margin-414.6%
Free Cash Flow MarginRevenue
$46.383m
+43.5%
1y CAGR+93.7%
3y CAGR+64.6%
5y CAGREarnings
-$199.835m
+15.7%
1y CAGR-2.8%
3y CAGR-5.8%
5y CAGREPS
-$2.38
+17.4%
1y CAGR+4.0%
3y CAGR-0.2%
5y CAGRBook Value
$13.453m
$201.751m
Assets$188.298m
Liabilities$19.652m
DebtDebt to Assets
9.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$180.703m
+17.5%
1y CAGR-6.0%
3y CAGR-5.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company